Exploring issues and opportunities in the development of platform technologies for oligonucleotide manufacturing
Nucleic Acid Insights · 2024
DOI: 10.18609/nai.2024.023 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acid Insights, 2024. Verfasst von Jeske Smink.
Abstract (Originalsprache)
David McCall, Senior Editor, Nucleic Acid Insights, speaks to Jeske Smink, Senior Director, Head of Drug Substance, about Silence Therapeutics’ platform-based approach to developing targeted short interfering RNA-based therapies. They discuss the current state-of-the-art in oligonucleotide manufacturing and CMC, and explore the emerging alternatives to the traditional solid-phase synthesis approach.
Zitieren
APA
Smink, J. (2024). Exploring issues and opportunities in the development of platform technologies for oligonucleotide manufacturing. Nucleic Acid Insights. https://doi.org/10.18609/nai.2024.023
Vancouver
Smink J. Exploring issues and opportunities in the development of platform technologies for oligonucleotide manufacturing. Nucleic Acid Insights. 2024. doi:10.18609/nai.2024.023
BibTeX
@article{Smink2024,
author = {Smink, Jeske},
title = {Exploring issues and opportunities in the development of platform technologies for oligonucleotide manufacturing},
journal = {Nucleic Acid Insights},
year = {2024},
doi = {10.18609/nai.2024.023}
}
EUVIMED